InterAx Overview

  • Status
  • Private

  • Employees
  • 17


  • Latest Deal Type
  • Later Stage VC
  • (Upcoming)

  • Investors
  • 10

InterAx General Information


Developer of a GPCR drug discovery platform designed to cover hit-generation and hit-to-lead for all GPCR targets including orphan GPCRs. The company's platform integrates high-throughput biochemical screening with artificial intelligence and cell signaling mathematical modeling, enabling the healthcare industry to identify and optimize drug candidates for a wide range of diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Corporate Office
  • Park Innovaare
  • 5234 Villigen
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InterAx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC Upcoming Pre-Clinical Trials
8. Later Stage VC 01-Nov-2022 00.000 Completed Pre-Clinical Trials
7. Grant 25-Nov-2019 00.000 00.000 Completed Pre-Clinical Trials
6. Seed Round 15-Jan-2019 00.000 00.000 000.00 Completed Pre-Clinical Trials
5. Seed Round 23-Dec-2016 00000 Completed Startup
4. Grant 21-Oct-2016 000.00 00000 Completed Startup
3. Accelerator/Incubator 01-Jan-2016 00000 00000 Completed Startup
2. Grant 01-Aug-2014 $167K Completed Startup
1. Spin-Off Completed Startup
To view InterAx’s complete valuation and funding history, request access »

InterAx Comparisons

HQ Location
Total Raised
Post Valuation
Developer of a GPCR drug discovery platform designed to cover hit-generation and hit-to-lead for all GPCR targets includ
Drug Discovery
Villigen, Switzerland
17 As of 2023
00000 00000


sequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum do
0000 000000000
San Diego, CA
000 As of 0000


g elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
0000 000000000
Oxford, United Kingdom
00 As of 0000
000.00 0000-00-00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InterAx Competitors (54)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vividion Therapeutics Formerly VC-backed San Diego, CA 000 00000 00000000
Sitryx Venture Capital-Backed Oxford, United Kingdom 00 000.00 0000000000 0 000.00
Monte Rosa Therapeutics Formerly VC-backed Boston, MA 000 00000 00000000 00000
Alzheon Venture Capital-Backed Framingham, MA 00 00000 00000000000 00000
Foghorn Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
You’re viewing 5 of 54 competitors. Get the full list »

InterAx Patents

InterAx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4238970-A1 Modulators of ackr3 and uses thereof Pending 03-Mar-2022 0000000000 0
EP-3878447-A1 Beta adrenergic receptor antagonists Inactive 11-Mar-2020 0000000000 0
JP-2022518549-A Beta-arrestin mutant Active 22-Jan-2019 0000000000 0
JP-7216216-B2 Beta-arrestin mutant Active 22-Jan-2019 0000000000 0
EP-3914916-A1 Beta-arrestin mutants Pending 22-Jan-2019 C07K14/723
To view InterAx’s complete patent history, request access »

InterAx Executive Team (9)

Name Title Board Seat
Aurélien Rizk Ph.D Co-Founder, Co-Chief Executive Officer & CSO
Christopher Prior Ph.D Co-Chief Executive Officer & Board Member
Luca Zenone Co-Founder, Chief Operating Officer, Chief Financial Officer and Board Member
Gebhard Schertler Co-Founder & Head of Scientific Advisory Board
Mirjam Zimmermann Ph.D Head of Research
You’re viewing 5 of 9 executive team members. Get the full list »

InterAx Board Members (6)

Name Representing Role Since
Bettina Ernst Ph.D Bernina BioInvest Board Member 000 0000
Christopher Prior Ph.D InterAx Co-Chief Executive Officer & Board Member 000 0000
Jens Gobrecht Ph.D Self Chairman 000 0000
Mark Levick Ph.D Self Board Member 000 0000
Yiannis Monovoukas Ph.D Falcon III Ventures Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

InterAx Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InterAx Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Convergence Partners (Switzerland) Venture Capital Minority 000 0000 000000 0
Plug and Play Tech Center Accelerator/Incubator Minority 000 0000 000000 0
Horizon 2020 SME Instrument Government 000 0000 000000 0
Bernina BioInvest Venture Capital Minority 000 0000 000000 0
Falcon III Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

InterAx FAQs

  • Who is the founder of InterAx?

    Aurélien Rizk Ph.D, Martin Ostermaier, Luca Zenone, and Gebhard Schertler are the founders of InterAx.

  • Who is the CEO of InterAx?

    Aurélien Rizk Ph.D and Christopher Prior Ph.D are the CEOs of InterAx.

  • Where is InterAx headquartered?

    InterAx is headquartered in Villigen, Switzerland.

  • What is the size of InterAx?

    InterAx has 17 total employees.

  • What industry is InterAx in?

    InterAx’s primary industry is Drug Discovery.

  • Is InterAx a private or public company?

    InterAx is a Private company.

  • What is InterAx’s current revenue?

    The current revenue for InterAx is 00000.

  • How much funding has InterAx raised over time?

    InterAx has raised $3.17M.

  • Who are InterAx’s investors?

    Convergence Partners (Switzerland), Plug and Play Tech Center, Horizon 2020 SME Instrument, Bernina BioInvest, and Falcon III Ventures are 5 of 10 investors who have invested in InterAx.

  • Who are InterAx’s competitors?

    Vividion Therapeutics, Sitryx, Monte Rosa Therapeutics, Alzheon, and Foghorn Therapeutics are some of the 54 competitors of InterAx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »